S&P Futures
4,046.75 -9.00 (-0.22%) Dow Futures
32,518.00 -82.00 (-0.25%) Nasdaq Futures
12,243.00 -36.25 (-0.30%) Russell 2000 Futures
1,833.30 -3.00 (-0.16%) Crude Oil
114.17 +0.08 (+0.07%) Gold
1,846.80 -0.80 (-0.04%)
Valneva SE (VALN)
Chart Events
Performance Outlook
| Previous Close | 23.06 |
| Open | 23.27 |
| Bid | 19.51 x 800 |
| Ask | 26.55 x 1200 |
| Day's Range | 23.02 - 23.82 |
| 52 Week Range | 19.45 - 67.84 |
| Volume | |
| Avg. Volume | 15,685 |
| Market Cap | 1.282B |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Related Research
- Valneva SEAnalyst Report: Alphabet Inc.Alphabet is a holding company, with Google, the Internet media giant, as a wholly owned subsidiary. Google generates 99% of Alphabet revenue, of which more than 85% is from online ads. Google’s other revenue is from sales of apps and content on Google Play and YouTube, as well as cloud service fees and other licensing revenue. Sales of hardware such as Chromebooks, the Pixel smartphone, and smart homes products, which include Nest and Google Home, also contribute to other revenue. Alphabet’s moonshot investments are in its other bets segment, where it bets on technology to enhance health (Verily), faster Internet access to homes (Google Fiber), self-driving cars (Waymo), and more. Alphabet’s operating margin has been 25%-30%, with Google at 30% and other bets operating at a loss.RatingFair ValueEconomic Moat9 hours agoMorningstar
- Zacks
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
- Motley Fool
Why Dynavax Stock Blasted 16% Higher Today
What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.
- MarketWatch
Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine
U.S.-listed shares of Valneva SE jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommendation from the EMA's Committee for Human Medicinal Products, the company said it expects a decision in June. The European Commission then decides whether to authorize the vaccine. Valneva's vaccine is an inactivated, whole-virus shot that was te
